GLP-1 Advertising Rules for Telehealth: What FDA and FTC Actions Mean for Your Merchant Account
FDA's warning letters, the FTC's NextMed case and ad-platform rules all read the same pages an underwriter reads. What you say in an ad ends up in your merchant account file.
Your GLP-1 ads are part of your merchant account. FDA's warning letters to telehealth sellers have cited claims that compounded drugs match approved ones, the FTC alleged that NextMed didn't adequately disclose costs and used fake testimonials, and underwriters read the same landing pages regulators do. A claim a regulator objects to can come back to you as a question from your processor.
GLP-1 advertising, for a telehealth merchant, is every claim made to sell a GLP-1 program: paid ads, landing pages, emails, social and affiliate content, and the checkout page itself. FDA's warning letters and the FTC's NextMed case have both addressed this marketing, and ad platforms apply their own healthcare policies on top.
What FDA has objected to in GLP-1 marketing
Claims that blur the line between a compounded product and an approved drug. FDA's page on unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026) and its warning letters to telehealth sellers set out the pattern:
| Claim or practice | What FDA has said | Where |
|---|---|---|
| Saying a compounded drug is the same as an FDA-approved drug | A red flag for consumers | FDA's GLP-1 concerns page |
| "Contains the same active ingredient as FDA-approved medications" | Cited in warning letters to telehealth sellers | Letters dated February 20 and June 8, 2026, among others |
| Branding that implies the telehealth company made the drug | Cited in warning letters | Same letters |
| Salt forms such as semaglutide sodium or semaglutide acetate | Different active ingredients; FDA is "not aware of any lawful basis for their use in compounding" | FDA's GLP-1 concerns page |
| Marketing unapproved drugs such as retatrutide | FDA has warned telehealth companies doing it | FDA's GLP-1 concerns page |
| Prices that seem too good to be true | A red flag for consumers | FDA's GLP-1 concerns page |
FDA has sent these letters in rounds, including September 2025, February 20, 2026 and June 8, 2026. Two examples are on fda.gov: the February 20, 2026 letter to Lean Rx Inc dba SkinnyRx and the June 8, 2026 letter to Altru Telehealth. A warning letter sets out FDA's concerns; it isn't a court finding. The letters address marketing. They aren't a ban on compounding, and what FDA has said about compounded semaglutide and tirzepatide themselves is in what FDA has said about compounded GLP-1s.
Read the table as a check on your pharmacy relationship as well as your copy. Two of the rows aren't wording problems at all. If a product in your catalog is a salt form or an unapproved drug, no rewrite of the ad fixes it. Labels are the same: FDA's page says some compounded products carry false label information, naming pharmacies that don't exist or didn't make the product. An underwriter who asks for your pharmacy agreements and product list can see what FDA would see. Answer those questions before an ad goes live, not after a letter arrives.
The same FDA page reports adverse events: as of May 31, 2026, 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide, numbers FDA says are likely under-reported.
What the FTC alleged in the NextMed case
That the program's price, results and terms were all presented misleadingly. In its July 2025 case, the FTC alleged that NextMed, a GLP-1 telehealth membership priced at around $138 or $188 a month:
- didn't adequately disclose that drugs, labs and consults cost extra;
- lacked substantiation for its claims about average weight loss;
- used fake testimonials and before-and-after photos;
- locked members into one-year terms billed every 28 days and made cancelling hard.
NextMed settled for $150,000, and the FTC later approved the final order. The counts were brought under sections 5 and 12 of the FTC Act, not under ROSCA. These were allegations, resolved by settlement rather than a ruling.
Each allegation also has a payments shadow, in our reading. Undisclosed costs can turn into "not as described" disputes (Visa Condition 13.3). Hard cancellation can turn into cancelled-recurring disputes (Condition 13.2). Unsupported results claims invite refund demands. How underwriters weigh all of this for a GLP-1 program is in payment processing for GLP-1 and weight-loss telehealth.
Ad platforms and LegitScript
LegitScript says its certification is necessary for advertising on Google and Bing. In its Healthcare Certification FAQ (read November 2026), it describes Meta, TikTok, LinkedIn and Netflix as "participating platforms" that apply their own policies, and says certification may be required for some ad programs without ensuring approval. Those are LegitScript's own statements about how the platforms use it; each platform's policy is the final word for that platform.
The same certification also figures in payments. LegitScript calls it "a necessary part of the approval process for conducting card-not-present transactions with Visa and Mastercard." Who is eligible, and what it costs, is in LegitScript certification for telehealth.
How an ad problem can reach your merchant account
Through the file, the disputes and the network rules. Our reading of how it travels:
- At application. Underwriters read your ads and landing pages as part of the file. A "same as" claim on the landing page is a question before you're boarded.
- Through public enforcement. FDA posts warning letters on fda.gov. A processor that finds one addressed to a merchant it boarded will have questions.
- Through disputes. Patients who were promised something the program didn't deliver can dispute charges, and dispute ratios are what acquirers and Visa monitor.
- Through Visa's rules. Visa §1.9.1.4 lets Visa permanently prohibit a merchant, or its principals, for non-compliance with the Visa Integrity Risk Program, including "illegal or brand-damaging" transaction activity.
None of these steps needs a court to find anything. An acquirer decides what it's willing to process, and a warning letter is enough to start that conversation.
A pre-launch ad-claims checklist
Run every ad, landing page and email past these questions before it goes live:
- Does anything say or imply that your compounded product is the same as an FDA-approved drug, or contains the same active ingredient?
- Does your branding suggest you make the drug, when a pharmacy partner does?
- Do you name the pharmacy that makes the product, and is that the pharmacy that actually made it?
- Are salt forms or unapproved drugs anywhere in your catalog or your ads?
- Does the advertised price say what's included and what costs extra, including medication, labs and consults?
- Can you substantiate every results claim, including averages?
- Are testimonials and before-and-after photos from real patients, used with permission?
- Are the membership term, billing interval and cancellation route stated before checkout, with an acknowledgement? Visa §5.4.2.5 requires that acknowledgement when you restrict cancellation or refunds.
- Does your LegitScript status match the platforms you plan to advertise on?
- Who approves new ads, and does your processor hear about material changes to what you sell?
This is a practical checklist, not legal advice; advertising counsel should review claims before launch. VyaPay's underwriting reads your marketing as part of the file, and because VyaPay runs its own processor, the people reading it are the team that makes the underwriting call. Talk to VyaPay before you launch.
Frequently asked questions
Can I say my compounded semaglutide is the same as the approved drug?
FDA lists that claim as a red flag, and its warning letters to telehealth sellers have cited "same active ingredient" language. Describe the product as what it is: compounded, by a named pharmacy.
Do FDA's warning letters mean compounded GLP-1s are banned?
The letters themselves aren't a ban; they address how the products were marketed. FDA's position on compounding them rests on separate statements about the end of the shortages and the limits in sections 503A and 503B.
Do I need LegitScript certification to run GLP-1 ads?
LegitScript says certification is necessary for Google and Bing. Meta, TikTok, LinkedIn and Netflix apply their own policies, per LegitScript, and certification doesn't ensure any platform approves an ad.
Can I use before-and-after photos in GLP-1 ads?
The FTC alleged NextMed used fake ones. Anything you use should come from real patients, with permission, and reflect results you can substantiate; advertising counsel can tell you what else applies.
Sources
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026
- FDA, Warning Letters (including Lean Rx Inc dba SkinnyRx, February 20, 2026, and Altru Telehealth, June 8, 2026)
- Federal Trade Commission, FTC v. NextMed, complaint and settlement, July 2025
- LegitScript, Healthcare Certification FAQ, read November 2026
- Visa, Visa Core Rules and Visa Product and Service Rules, 24 October 2026 (sections 1.9.1.4 and 5.4.2.5)
